Antischistosomal drugs: Past, present … and future?
- 1 January 1995
- journal article
- research article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 68 (1) , 35-85
- https://doi.org/10.1016/0163-7258(95)00026-7
Abstract
No abstract availableKeywords
This publication has 230 references indexed in Scilit:
- Mutation at the HPRT locus in patients with neurocysticercosis treated with praziquantelMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1994
- Evaluation of the carcinogenic and genotoxic potential of praziquantel in the Syrian hamster embryo cell transformation assayMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1994
- Oltipraz: A laboratory and clinical reviewJournal of Cellular Biochemistry, 1993
- Metabolism studies of the antischistosomal drug praziquantel using tandem mass spectrometry: Distribution of parent drug and ten metabolites obtained from control and schistosome-infected mouse urineJournal of Mass Spectrometry, 1990
- Evidence for the mode of antischistosomal action of hycanthoneLife Sciences, 1985
- Covalent binding of niridazole (ambilhar) to tissue proteins of the ratChemico-Biological Interactions, 1984
- Chemistry of Metrifonate and DichlorvosActa Pharmacologica et Toxicologica, 1981
- Variation of the supercoils in closed circular DNA by binding of antibiotics and drugs: Evidence for molecular models involving intercalationJournal of Molecular Biology, 1970
- A possible metabolic basis for the schistosomicidal activity of Mirasan and N-(3-chloro-4-methylphenyl)-piperazineLife Sciences, 1967
- The New Insecticide O,O-Dimethyl 2,2,2-Trichloro-1-hydroxyethylphosphonateJournal of the American Chemical Society, 1955